Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Conrad-Amadeus VoltinAndrea PaccagnellaMichael WinkelmannJan-Michel HegerBeatrice CasadeiLaura BeckmannKen HerrmannFranziska J DekorsyNadine KutschPeter BorchmannStefano FantiWolfgang G KunzMarion SubkleweCarsten KobePier Luigi ZinzaniMatthias StelljesKatrin S RothAlexander DrzezgaRichard NoppeneyKambiz RahbarH Christian ReinhardtBastian von TresckowRobert SeifertJörn C AlbringViktoria BlumenbergAndrea FarolfiSarah FlossdorfPhilipp GödelChristine HanounPublished in: European journal of nuclear medicine and molecular imaging (2023)
Our analysis demonstrates that the presence of more than one extra-nodal lesion and higher MTV in LBCL are associated with inferior outcome after CAR T-cell treatment. Based on an assessment tool including these two factors, patients can be assigned to one of three risk groups. Importantly, as shown by our study, metabolic tumor burden might facilitate CAR T-cell product selection and reflect the individual need for bridging therapy.
Keyphrases
- cell therapy
- risk assessment
- patients undergoing
- end stage renal disease
- ejection fraction
- chronic kidney disease
- stem cells
- mesenchymal stem cells
- computed tomography
- diffuse large b cell lymphoma
- squamous cell carcinoma
- heavy metals
- clinical trial
- risk factors
- pet ct
- human health
- climate change
- neoadjuvant chemotherapy
- bone marrow